Two Sigma Advisers LP Purchases 970,700 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Two Sigma Advisers LP increased its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 94.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,998,317 shares of the company's stock after purchasing an additional 970,700 shares during the period. Two Sigma Advisers LP owned approximately 1.96% of Intellia Therapeutics worth $23,300,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Sterling Capital Management LLC grew its position in shares of Intellia Therapeutics by 866.2% during the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company's stock worth $37,000 after buying an additional 2,867 shares during the period. Whipplewood Advisors LLC bought a new position in Intellia Therapeutics during the 4th quarter worth approximately $40,000. Resona Asset Management Co. Ltd. acquired a new position in Intellia Therapeutics during the fourth quarter valued at approximately $43,000. Jones Financial Companies Lllp increased its stake in Intellia Therapeutics by 140.9% in the fourth quarter. Jones Financial Companies Lllp now owns 3,898 shares of the company's stock valued at $45,000 after purchasing an additional 2,280 shares in the last quarter. Finally, Daiwa Securities Group Inc. raised its holdings in Intellia Therapeutics by 80.6% in the fourth quarter. Daiwa Securities Group Inc. now owns 5,151 shares of the company's stock worth $60,000 after purchasing an additional 2,299 shares during the period. Institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Price Performance

NTLA stock traded down $0.30 during mid-day trading on Monday, reaching $9.16. The company had a trading volume of 2,184,137 shares, compared to its average volume of 2,568,653. The stock has a 50 day simple moving average of $7.98 and a two-hundred day simple moving average of $10.51. The company has a market capitalization of $948.82 million, a price-to-earnings ratio of -1.68 and a beta of 2.33. Intellia Therapeutics, Inc. has a 52 week low of $5.90 and a 52 week high of $28.18.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, beating analysts' consensus estimates of ($1.26) by $0.16. The business had revenue of $16.63 million during the quarter, compared to the consensus estimate of $11.39 million. During the same quarter last year, the company posted ($1.12) EPS. The firm's revenue was down 42.6% on a year-over-year basis. On average, equities analysts predict that Intellia Therapeutics, Inc. will post -5.07 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on NTLA. Guggenheim decreased their price target on shares of Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating for the company in a report on Monday, May 12th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price target on shares of Intellia Therapeutics in a research report on Tuesday, May 20th. Wall Street Zen upgraded Intellia Therapeutics to a "sell" rating in a report on Monday, March 3rd. JPMorgan Chase & Co. reissued a "neutral" rating and set a $13.00 target price (down from $45.00) on shares of Intellia Therapeutics in a research note on Friday, February 28th. Finally, Truist Financial cut their price target on shares of Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Intellia Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $36.90.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.